Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Therapeutic indication before entering the enrollment face is patients diagnosed with COPD requiring a combination therapy of two long-acting bronchodilators (LAMA + LABA) according to approved SmPC and guidelines, COPD GOLD 2017 groups B to D
Female and male patients ≥40 years of age
Treatment with Spiolto ® Respimat® acc. to SmPC and at the discretion of the physician
Written informed consent prior to participation
You may not be if
Patients with contraindications according to Spiolto® Respimat® SmPC
Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 weeks or patients already on a combination of LAMA and LABA therapy; either as a fixed combination product or as separate components Note: Patients previously treated with LABA or LAMA (with or without ICS) are eligible to be included in the study
Patients continuing LABA-ICS treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists
Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks
Pregnancy and lactation
Patients currently listed for lung transplantation
Current participation in any clinical trial or any other non-interventional study of a drug or device
